<DOC>
	<DOCNO>NCT00935298</DOCNO>
	<brief_summary>Acute rejection ( AR ) main complication transplantation , severe risk chronic rejection implant devitalization . Tacrolimus ( FK506 ) immunosuppressant use prevention episode acute rejection . Tacrolimus characterize narrow therapeutic index important interindividual variation pharmacokinetic characteristic . Tacrolimus metabolize liver cytochrome P450 system , cytochrome P450 3A5 ( CYP 3A5 ) isoenzyme specifically . Polymorphisms CYP 3A5 gene associate change metabolic function translate isoenzyme . These polymorphism result metabolism acceleration tacrolimus compare subject wild type gene , consequently lead insufficiency tacrolimus ; theorize lead high risk acute rejection . Several retrospective study suggest association genetic polymorphism CYP3A5 interindividual variation tacrolimus blood concentration . In particular , initial study show adult renal transplant recipient CYP3A5*1/*3 *1/*1 （expressors） genotype require high , fix , start dose compare CYP3A5*3/*3 （nonexpressor）to reach predefined target exposure early transplantation . This prospective study design evaluate whether genetic test CYP 3A5 improve tacrolimus initiation well usual care . This study prospective , multicentric , open , parallel , efficacy study . 300 receiver renal transplant 8 centre include . The genotyping gene CYP3A5 carry 4-7days renal transplantation . After transplantation , patient treat MMF , corticosteroid tacrolimus dosage adapt genotype ( 0.15mg/kg/d CYP3A5*1/*1 type CYP3A5*1/*3 type，0.08mg/kg/d CYP3A5*3/*3 type ) . The determination tacrolimus blood concentration carry Day 3,5,7,14,18,21,28,35,49,63,77,90 . The daily amount tacrolimus could modify necessary reach desire blood concentration . The total duration study patient 3 month transplantation . The objective study determine initial dosage tacrolimus Chinese renal transplantation patient genotyping cytochrome P450 3A5</brief_summary>
	<brief_title>Initial Dosage Range Tacrolimus Genotyping Chinese Renal Transplantation</brief_title>
	<detailed_description>VISITS The participation patient study 3 month . For period , 9 visit plan •Before transplantation Visit 1 : inclusion visit ( 4-7 day transplantation ) , A blood take carry EDTA tube CYP 3A5 genotyping 4-7 day renal transplantation . • After transplantation Visit 2 : D3 Visit 3 : D5 Visit 4 : D7 Visit 5 : D14 Visit 6 : D21 Visit 7 : M1 + - 3 day Visit 8 : M2 + - 3 day Visit 9 : M3 + - 3 day Treatment After transplantation , patient treat MMF , corticosteroid tacrolimus dosage adapt genotype ( CYP3A5*1/*1 type CYP3A5*1/*3 type administer 0.15mg/kg/d，CYP3A5*3/*3 type administer 0.08mg/kg/d ) . The MMF give accord weight 3 month transplantation follow : 50 kilogram ( kg ) 0.25g bid ( 0.5g pre day ) 50~70kg 0.50g bid ( 1.0g pre day ) 70~90kg 0.75g bid ( 1.5g pre day ) Exceed 90kg 1.0g bid ( 2.0g pre day ) Corticosteroid therapy decrease amount follow : D0 - D15 : 20 Mg D16 - D30 : 15 Mg D30 - D45 : 10 Mg D46 - M3 5 Mg The determination tacrolimus blood concentration carry Day 3,5,7,14,18,21,28,35,49,63,77,90 . The daily amount Tacrolimus could modify necessary reach desire blood concentration . The total duration study patient 3 month transplantation . If present study able confirm advantage genotype-driven algorithm , term improve efficiency , therapeutic efficacy , especially , safety , pharmacogenetics approach dose recommend basis wide quality improvement initiative improve patient outcome , reduce resource use ( cost achieve safe therapeutic immunosuppression ) , reduce adverse clinical event .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients renal inadequacy , necessary receive renal transplantation , male female , 18 65 year old ; Patients receive first isolate renal graft administration FK506 ; Patient willing provide inform consent prior specimen collection procedure . Patients receive another clinical pharmaceutical study le 3 month entry study , already complete drop study . Patients contraindication FK506 immunosuppressive therapy : pregnancy allergic intolerant FK506 macrolides . Patients suffer severe disease cardiovascular system ( essential hypertension ) , liver ( anamnesis type B hepatitis , type C hepatitis ) , hemopoietic system , nervous system , psychotic . Patients interfere blood concentration FK506 administration cytochrome P4503A4 P4503A5 enzyme inhibitor , lidocaine , midazolam , nicardipine , niludipine , cortisone , itraconazole , fluconazole , ketoconazole , miconazole , clotrimazole ，Bromocriptine . Patients anaemia ( hemoglobin low 7g/dl ) . Patients Diagnosed DM . Patients interfered capacity absorb FK506 anorexia nervosa , malabsorption syndrome gastrointestinal resection accord viewpoint investigator . Patients lack understanding medicinal knowledge tacrolimus risk study accord viewpoint investigator . Patients allergic constitution history serious allergy . Patients bad compliance accord viewpoint investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>CYP3A5</keyword>
	<keyword>Genotyping</keyword>
</DOC>